Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NAAA | Q02083 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MLYCD | O95822 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15782158 | 0.95 | L3MBTL1 (0.79) | L3MBTL1LMNAPOLBSMN1; SMN2NAAA | |
| SCHEMBL13577911 | 0.95 | L3MBTL1 (0.97) | L3MBTL1LMNAPOLBSMN1; SMN2NAAA | |
| SCHEMBL24220267 | 0.93 | L3MBTL1 (1.00) | L3MBTL1LMNAPOLBSMN1; SMN2NAAA | |
| SCHEMBL8208835 | 0.93 | L3MBTL1 (1.00) | L3MBTL1LMNAPOLBSMN1; SMN2NAAA | |
| SCHEMBL7961787 | 0.93 | L3MBTL1 (1.00) | L3MBTL1LMNAPOLBSMN1; SMN2NAAA | |
| SCHEMBL28326194 | 0.92 | L3MBTL1 (0.73) | L3MBTL1SMN1; SMN2NAAANPC1RAB9A | |
| SCHEMBL9489979 | 0.89 | L3MBTL1 (0.86) | L3MBTL1LMNAPOLBSMN1; SMN2NAAA | |
| SCHEMBL765958 | 0.89 | L3MBTL1 (0.74) | L3MBTL1LMNAPOLBSMN1; SMN2NPC1 | |
| SCHEMBL11220601 | 0.86 | LMNA (0.85) | L3MBTL1LMNAPOLBSMN1; SMN2NPC1 | |
| SCHEMBL22919705 | 0.85 | L3MBTL1 (0.65) | L3MBTL1SMN1; SMN2NAAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115304506-B | Preparation method of secondary amide compound by activating primary amide through boron salt catalysis | 中国人民解放军国防科技大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-115974711-A | Preparation method of aryl amide compound by using aromatic ester catalytically activated by boron salt | 湖南农业大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-115304506-A | Preparation method of secondary amide compound by activating primary amide under catalysis of boron salt | 中国人民解放军国防科技大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-104761420-B | Method for synthesizing amide from methyl aromatic hydrocarbon and amine in water phase | 江西师范大学 | 2021-03-05 | — | — | CN | disclosed |
| EP-3233041-B1 | COSMETIC PROCESS FOR ATTENUATING WRINKLES | OREAL (FR) | 2019-01-30 | — | — | EP | disclosed |
| US-20170035893-A1 | ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE | 2017-02-09 | — | — | US | disclosed |
| CN-104761420-A | Method of synthesizing amide with methyl aromatics and amine in water phase | UNIV JIANGXI NORMAL | 2015-07-08 | — | — | CN | disclosed |
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-4160095-A | PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| US-4157441-A | PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035893-A1 | ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF | AASDHPPT, CA13, CA12 | L3MBTL1 4502/4885LMNA 1646/4885POLB 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.